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1. Introduction
The term polycystic ovarian disease is a misnomer. The question whether it is a disease whole 
by itself or a sign of a wider disease complex has eluded many physicians from early 1900s. 
The insult to the normal physiology occurs in adolescence or the cause is deep rooted during 
the genesis of life; that is, fertilization and embryo formation are not clear yet. It is said that 
a person diagnosed with polycystic ovarian disease in adulthood can have signs and symp-
toms of metabolic syndrome in future. It is one disease that affects an young girl who is being 
bullied for her hairy faces, and blisters on her faces to a women who is trying hard to work 
with her irregular and scanty periods, to women hoping to become pregnant and have a baby 
and to a middle aged women who has to remember to take her daily dosage of antihyperten-
sive medication. With increasing number of patients presenting with symptoms of polycystic 
ovarian disease, the day is not far when it will become an emerging medical challenge.
2. The challenges in diagnosis
There has been long debate regarding the definition and diagnostic criteria of polycystic ovar-
ian disease. The diagnostic criteria can be dated back to 1990, when National Institute of Child 
Health and Human Development (NICHD) gave the first working diagnostic criteria [1].The 
NICHD criteria was based on majority opinion and was not on clinical trial [2]. Polycystic 
morphology of the ovaries was a consistent finding in women demonstrating biochemical 
and clinical evidence of the syndrome [3–6] that was not included in NICHD criteria. Then 
came the guideline by European Society for Reproduction and Embryology (ESHRE) and 
the American society for Reproductive Medicine (ASRM) criteria in 2003, which included 
the ultrasonographic finding of polycystic ovaries. The Rotterdam criteria are controversial. 
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Fulfilling two of three diagnostic criteria implies that PCOS can be diagnosed in the absence 
of androgen excess or menstrual irregularity—the very factors that were once considered 
absolute requisite for the syndrome [7]. Task force appointed by the Androgen Excess and 
PCOS society in 2006 considered the menstrual disorder and the ultrasonography finding 
of polycystic ovaries to be the presentation of similar pathophysiology and considered them 
to be one. At present, there is no definitive diagnostic criteria for polycystic ovarian disease 
rather it is a diagnosis of exclusion [7]. For evaluation of hyperandrogenemia, there is no con-
sensus about which testosterone to be measured, when to be measured, what range should 
be taken, and what method of measurement is to be used. For features of hyperandrogen-
ism assessment of hirsutism, acne and alopecia are more of subjective feature. Assessment 
of menstrual irregularities and serum progesterone for anovulation is also not confirmatory. 
Ultrasonographic findings of polycystic ovary are also subjective. None of the above criteria 
states for diagnosis of polycystic disease in adolescents where these features could be present 
due to pubertal changes [8–10].
3. The challenges for pathophysiological basis
There has been extensive work on finding the etiology and pathophysiology behind this dis-
ease. None could find exact etiology behind this. There is halt in the dynamic endocrinal 
milieu of the ovary [1]. There is increase in both LH pulse frequency and production of more 
bioactive LH, and there is increased LH:FSH ratio leading to neuroendocrinologic origin 
hypothesis. The feedback signal from periphery may be inappropriate or there may be intrin-
sic hypothalamic dysfunction [1]. Hyperandrogenemia came into scene while searching for 
a cause of both aberrant peripheral feedback and dysfunctional hypothalamus. The rises in 
androgen were both from ovary and adrenal glands, shifting the focus on ovarian pathology 
[11–14]. Some attribute the chronic anovulation to be the cause of hyperandrogenemia, and 
some authors say the other way. Insulin resistance causes hyperandrogenemia. Insulin causes 
selective stimulation of receptor that causes hyperandrogenemia. About 35% of patients have 
impaired glucose tolerance and 7–10% have diabetes mellitus [1]. It is a more common finding 
in obese polycystic disease patient than in lean PCOS patient. Nearly 25–50% of women with 
PCOS have no demonstrable insulin resistance. Approximately 60% of women with PCOS 
are obese. The prevalence of PCOS is comparable in women with BMI <18.5, normal weight 
women, and BMI 25–30 and BMI ≥30 [1]. Modern lifestyle and obesity can also be the cause. 
Recent researchers are giving significance to the genetic cause. There are genetic and nonge-
netic theories for etiopathogenesis of polycystic ovarian disease. Recently, two-hit hypothesis 
has been given. Patient presenting with PCOS are thought be genetically predisposed, and 
after environmental insult, they become symptomatic. Genetic predisposition can be because 
of mutations affecting ovarian function, female virilization, or intrauterine nutritional sta-
tus of fetus. Environmental insult can be hyperinsulinemia, obesity, and others. There has 
been evolutionary theory behind PCOS; to compensate for hyperandrogenemia in male, there 
was evolutionary decrease in female fertility and also that in the process of evolution a more 
androgenic environment helped nutritionally deprived population to reproduce which in 
today’s scenario is not beneficial [11].
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4. The challenges in treatment and outcome
As cause and pathophysiology is not clear, the treatment ranges widely from only lifestyle modi-
fication to planned use of insulin sensitizers like metformin to desperate ovarian drilling, there is 
also indecisiveness about the usefulness of present treatment methods in ameliorating long-term 
complications like endometrial carcinoma. A simple initial step of losing weight can return ovu-
lation in patients. Losing weight alone does not cure other symptoms. For menstrual irregular-
ity, continuous or cyclical hormonal therapy can be used. For infertility treatment, simple weight 
loss can return ovulation or patients have many time opt for in-vitro fertilization. Metformin as 
primary drug for ovulation is controversial though it improves insulin-resistant status.
The determinants for calculating the prognosis of the patient are also not clear. With different 
age of population presenting with different presentation and with people at increased risk for 
variety of problems like infertility, dysfunctional bleeding, endometrial cancer, obesity, type 2 
diabetes mellitus, dyslipidemia, hypertension, and cardiovascular disease, it is difficult to frame 
a prognostic criteria.
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